All In Biotech

Drug Trial Radar · NCT05108025

DMT310-005 Topical in the Treatment of Acne Rosacea

A Study Of The Tolerability, Safety, And Efficacy Of DMT310 For The Treatment Of Acne Rosacea

Last checked: Nov 19, 2026Latest source record: Dec 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

180

Actual

Start

Nov 15, 2021

Primary completion

Dec 2022

Study completion Dec 2022

Sponsor

Lead sponsor
Dermata TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne rosacea.

Conditions

  • Acne Rosacea

Interventions

  • Topical PowderDrug

    Topical Powder mixed with diluent

  • Placebo Topical PowderDrug

    Placebo Topical Powder mixed with diluent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy as measured by lesion countsTime frame: 12 Weeks
  2. Efficacy as measured by Investigator Global Assessment (IGA)Time frame: 12 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermata Investigational Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.